Profusa
San Francisco, US · 1 known investors
Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue. The company's Lumee platform addresses oxygen monitoring for vascular surgery patients and continuous glucose monitoring for diabetes and prediabetes patients.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Founders & leadership
BH
Ben HealyCEO
BF
Bill FawcettCo-founder
FC
Fred Craven
DK
Dr. Katharine Rebrin
AT
Aude Taibi
SP
Sean Patterson
Investors · 1
In the news
- Profusa CEO urges shareholders to vote on Nasdaq listing proposals By Investing.cominvesting.com · 2026
- Profusa (PFSA) registers 179.3M resale shares, up to $100M ELOC fundingstocktitan.net · 2026
- Profusa raises 2026 revenue forecast on European purchase orders By Investing.cominvesting.com · 2026
- Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidanceglobenewswire.com · 2026